secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001558370-25-003143
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix increases ATM equity offering capacity by $20M for general corporate purposes
--------------------------------------------------------------------------------

- Amendment with H.C. Wainwright increases ATM offering capacity by $20M in aggregate gross sales price.
- Net proceeds will be used for general corporate purposes, including working capital and clinical trials.
- Prospectus supplement filed to register additional shares under existing shelf registration statement.
- No shares were previously available for sale under the existing Sales Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025003143/0001558370-25-003143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025003143/plx-20250317x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer